Viral vector demand to flourish on wave of imminent approvals, CPHI Worldwide audience told
Expected increase in approvals for gene therapies, gene-modified cell therapies and recombinant vector vaccines will also increase pressure on manufacturers to build new capacity
An imminent wave of approvals for pipeline gene therapies, gene-modified cell therapies and recombinant vector vaccines is set to give a further boost to growing demand for viral vectors but will also increase the pressure on manufacturers to expand capacity, delegates at the CPHI Worldwide online conference were told Monday.
In the live session, Building Viral Vector Capacity and Capabilities to Realise the Promise of Gene Therapies sponsored by Thermo Fisher Scientific, experts discussed how continuing advances in cell and gene therapy are transforming how biopharma companies treat and potentially cure certain diseases in this fast-evolving field.
Viral vectors are the carriers used to deliver genetic material to cells to prevent or fight disease and are commonly used by gene therapies and recombinant vector vaccines.
Peter Shapiro, Senior Director of Drugs and Business Fundamentals at GlobalData said there were currently more than 3,000 pipeline gene therapies, gene-modified cell therapies and recombinant vector vaccines in the development pipeline from the discovery stage to the pre-registration stage.
He added that using GlobalData’s Likelihood of Approval tool which tracks and predicts the likelihood of approval and phase transition success using Machine Learning and proprietary models, “if we look at this list of 3,000+ drugs and narrow it down to the ones in the clinical phase, we estimate that more than 100 of these gene/gene-modified cell therapies will eventually be approved – this will push viral vector demand even higher.”
Shapiro said that in response to rising demand, CDMOs had started to build manufacturing capacity for viral vectors, but compared with monoclonal antibody therapies, there was relatively little capacity with less than 100 contract viral vector facilities worldwide, the majority of which are in the US.
Chris Murphy, Vice President and General Manager of Viral Vector Services at Thermo Fisher Scientific said around 60% of innovative biopharma companies were currently outsourcing viral vector production due to differences in facility requirements and the need for specialist expertise.
“This industry blew up in the last five years and it really didn’t have the capacity or capabilities initially,” he said. “There’s a lot of expertise at innovators and it’s not that different from biologics production per se but there is a tendency to outsource because that is where the expertise lies.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance